Structure Therapeutics (NASDAQ:GPCR) Shares Down 5.4% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares traded down 5.4% during mid-day trading on Wednesday . The company traded as low as $36.82 and last traded at $36.8530. Approximately 313,859 shares changed hands during trading, a decline of 65% from the average daily volume of 896,918 shares. The stock had previously closed at $38.95.

Analyst Ratings Changes

Several research analysts recently commented on GPCR shares. Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Trading Down 5.4%

The company has a 50 day moving average of $48.94 and a 200 day moving average of $48.03. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -36.89 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GPCR. IFP Advisors Inc acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at approximately $46,000. Squarepoint Ops LLC lifted its stake in Structure Therapeutics by 454.5% in the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after buying an additional 102,929 shares in the last quarter. Seven Fleet Capital Management LP lifted its stake in Structure Therapeutics by 197.8% in the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock valued at $1,442,000 after buying an additional 17,800 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics during the second quarter worth $1,041,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.